PMID- 38180132
OWN - NLM
STAT- MEDLINE
DCOM- 20240411
LR  - 20240411
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 204
IP  - 4
DP  - 2024 Apr
TI  - Venetoclax and hypomethylating agents in critically ill patients with newly 
      diagnosed acute myeloid leukaemia.
PG  - 1219-1226
LID - 10.1111/bjh.19291 [doi]
AB  - Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is considered 
      the standard of treatment for individuals with newly diagnosed acute myeloid 
      leukaemia (AML) who are ineligible for intensive chemotherapy. We conducted a 
      retrospective analysis that encompassed 16 critically ill patients newly 
      diagnosed with AML who were admitted to the intensive care unit (ICU) and 
      received the VEN and HMA regimen. Among them, 13 were primary AML, and three were 
      MDS-transformed AML. The mean Acute Physiology and Chronic Health Evaluation II 
      (APACHE II) score was 18.9, and the mean sepsis-related organ failure assessment 
      score (SOFA) was 6.2. The average length of the ICU stay was 27.3 days. The 
      median duration of VEN administration was 16 days. After the first course of 
      VEN + HMA, 12 cases (75%) achieved complete remission (CR) or CR with incomplete 
      haematological recovery (CRi). Among the five patients harbouring TP53 mutations, 
      the overall response rate (ORR) was 90%. All patients experienced grade 3-4 
      haematological adverse events (AEs). With a median follow-up of 9.5 months 
      (range: 0.5-23), the overall survival (OS) rate was 43.75%. TP53-wild patients 
      and CR state after the first course of VEN-HMA indicated better survival. The 
      combination of VEN and HMA has demonstrated a significantly elevated therapeutic 
      response rate in newly diagnosed AML patients with critical illness.
CI  - (c) 2024 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Liang, Peiqi
AU  - Liang P
AUID- ORCID: 0000-0001-5329-6771
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Xie, Yan
AU  - Xie Y
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Liu, Ziyi
AU  - Liu Z
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Wang, Dong
AU  - Wang D
AUID- ORCID: 0000-0002-4047-8987
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Li, Qian
AU  - Li Q
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Lu, Yin
AU  - Lu Y
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Xue, Shengli
AU  - Xue S
AUID- ORCID: 0000-0003-4609-616X
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Chen, Suning
AU  - Chen S
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Wu, Deipei
AU  - Wu D
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
FAU - Fu, Jianhong
AU  - Fu J
AUID- ORCID: 0000-0002-9044-024X
AD  - National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of 
      Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 
      China.
AD  - Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of 
      Hematology, Soochow University, Suzhou, Jiangsu, China.
LA  - eng
GR  - 82300246/National Natural Science Foundation of China/
GR  - H211284/Transverse Research of Soochow University/
PT  - Journal Article
DEP - 20240105
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - N54AIC43PW (venetoclax)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Sulfonamides)
SB  - IM
MH  - Humans
MH  - *Critical Illness
MH  - Retrospective Studies
MH  - Bridged Bicyclo Compounds, Heterocyclic/adverse effects
MH  - *Leukemia, Myeloid, Acute/genetics
MH  - Pathologic Complete Response
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Sulfonamides
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - hypomethylating agents
OT  - intensive care unit
OT  - venetoclax
EDAT- 2024/01/05 12:43
MHDA- 2024/04/11 06:43
CRDT- 2024/01/05 09:50
PHST- 2023/12/10 00:00 [revised]
PHST- 2023/11/08 00:00 [received]
PHST- 2023/12/23 00:00 [accepted]
PHST- 2024/04/11 06:43 [medline]
PHST- 2024/01/05 12:43 [pubmed]
PHST- 2024/01/05 09:50 [entrez]
AID - 10.1111/bjh.19291 [doi]
PST - ppublish
SO  - Br J Haematol. 2024 Apr;204(4):1219-1226. doi: 10.1111/bjh.19291. Epub 2024 Jan 
      5.